echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > Cansino: 13-valent pneumococcal polysaccharide conjugate vaccine enters phase III clinical trial

    Cansino: 13-valent pneumococcal polysaccharide conjugate vaccine enters phase III clinical trial

    • Last Update: 2021-05-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On April 13, Cansino announced that the 13-valent pneumococcal polysaccharide conjugate vaccine developed by the company has completed preparations for phase III clinical trials and officially entered phase III clinical trials.


    Pneumococcal disease is one of the serious public health problems in the world.


    The main pathogens of serious diseases such as inflammation, meningitis, and bacteremia are also common causes of acute otitis media and sinusitis .
    In developed countries and regions, the introduction and widespread use of pneumococcal polysaccharide conjugate vaccines have effectively controlled serious diseases caused by Streptococcus pneumoniae.
    However, in Africa and Asia, the number and proportion of children under 5 years of age are still relatively high.
    WHO recommends that countries around the world should the pneumococcal polysaccharide conjugate vaccine into this child immunization programs of countries, especially in countries with high child mortality should introduce multi-antigen polysaccharide pneumococcal conjugate vaccine in national immunization programs as a high-priority project.
    In the "Global Action Plan for the Prevention and Control of Pneumonia " (GAPP), WHO puts forward the goal of "eliminating preventable pneumonia-induced deaths in children by 2025".
    The introduction of pneumococcal polysaccharide conjugate vaccine is the main means to achieve this goal.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.